Skip to main content

A Phase 3, randomised, double-blind, parallel-group, event driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD

Open
  • Protocol code: 1404-0040
  • EudraCT code: No aplica
  • Research group: Diabetes and Metabolism
  • Service: Endocrinology
  • Principal investigator:  Simó Canonge, Rafael
  • Pathology: Malalties endocrines, nutricionals i metabòliques
  • Phase: Fase III